RGT Argent Biopharma Limited

21 June 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

Appointment of UK Corporate Broker

Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector, is pleased to announce the appointment of Shore Capital Stockbrokers Limited as the Company's UK Corporate Broker with immediate effect.

Roby Zomer, CEO & Managing Director of Argent BioPharma, commented:

"We are delighted to announce the appointment of Shore Capital as our new UK Corporate Broker. This is a further step in our comprehensive restructuring process to position Argent BioPharma in pioneering drug discovery within the biopharmaceutical sector, supported by the strengthening of our management team and advisory board. We look forward to working with the team at Shore Capital as we seek to enhance our visibility and engagement with investors."

-Ends-

Authorised for release by the board of directors, for further information please contact:

About Argent BioPharma

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; ORCQB: RGTLF) is a Clinical-Stage, Revenue Generating Biopharmaceutical Company committed to providing accessible medical treatments for unmet medical needs, to bridge the gap where medical solutions currently fall short.  The Group focuses on the Multidisciplinary method with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially relating to the Central nervous system ("CNS") and Immunology treatments.

About Shore Capital

Shore Capital is an independent securities business offering investment banking, research, sales and trading services to companies on both the Main Market and AIM.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma